drugset / Trial / NCT05382728
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
Timeline
- Start
- 2022-06-08
- Primary completion
- 2025-05
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | TY-9591 | Unknown | 160 mg | Oral |